{"schema_version":"secwatch.filing_event.v1","accession":"0000917520-25-000038","form_type":"8-K","ticker":"IART","cik":"0000917520","company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.806677+00:00","generated_at":"2026-05-22T21:45:39.003615+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Integra LifeSciences Q1 2025: Adj EPS $0.41 vs $0.55 YoY; organic revenue down 3.5%","bullets":["Revenue of $382.7M up 3.7% reported but down 3.5% organic; GAAP net loss $(0.33)/share vs $(0.04).","Adjusted EPS $0.41 vs $0.55 prior year; adjusted gross margin 62.2% vs 64.4%.","Codman Specialty Surgical organic revenue -1.1%; Tissue Technologies organic -9.1%.","Full-year 2025 revenue reaffirmed $1.65B-$1.715B; adj EPS guidance reduced to $2.19-$2.29 (incl $(0.22) tariff impact).","Q2 2025 guidance: revenue $390M-$400M, adj EPS $0.40-$0.45; operating cash flow negative $(11.3)M."],"urls":{"canonical":"https://secwatch.observer/filing/0000917520-25-000038","json":"https://secwatch.observer/filing/0000917520-25-000038.json","markdown":"https://secwatch.observer/filing/0000917520-25-000038.md","text":"https://secwatch.observer/filing/0000917520-25-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/917520/000091752025000038/0000917520-25-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/917520/000091752025000038/iart-20250505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T21:45:39.003615+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}